TORONTO, Ontario, Canada and BENGALURU, Karnataka, India, June 27, 2025 (GLOBE NEWSWIRE) -- Biocon Biologics Ltd. (BBL), a ...

Biocon Biologics secures Health Canada approval for Yesafili, the first biosimilar to Eylea® in Canada, with a global launch scheduled for July 4, 2025, targeting treatment of serious eye diseases.

The additional presentation is approved for the treatment of pediatric patients aged 6 to 17 years with plaque psoriasis or ...

The Global Prefilled Syringes Market is expected to witness a high single-digit growth rate by 2027. The growth of the prefilled syringes market is driven by an increasing prevalence of diverse ...

Counterfeit drugs, including cosmetic injectables, weight-loss drugs, and ivermectin tablets, have been seized at Australia’s ...

The prefilled syringe drug molecule market has seen significant evolution as healthcare systems globally strive for safer, more efficient drug delivery methods. Prefilled syringes offer an innovative ...

FDA approved Vyvgart Hytrulo prefilled syringe for gMG and CIDP self-injection in 20–30 seconds. Human factor studies showed patients and caregivers safely administered the new formulation. Live ...

NEW YORK, DE, UNITED STATES, June 12, 2025 /EINPresswire.com/ -- The global prefilled syringe drug molecule market is projected to expand from USD 74.38 billion in 2025 to approximately USD 133.24 ...

The EC has approved argenx’s Vyvgart (efgartigimod alfa) 1000mg as a single agent for subcutaneous injection to treat CIDP.

The global prefilled syringes market share is projected to grow from US$ 6.69 Billion in 2022 to US$ 15.0 Billion by 2030, driven by the increasing p. Tuesday, 02 January 2024 12:17 GMT.

The European Commission (EC) has approved argenx’s Vyvgart (efgartigimod alfa) subcutaneous (SC) injection to treat chronic ...